COSMOS Pharmaceutical Corporation Stock

Equities

3349

JP3298400007

Drug Retailers

Market Closed - Japan Exchange 02:00:00 2024-04-26 EDT 5-day change 1st Jan Change
14,390 JPY -0.79% Intraday chart for COSMOS Pharmaceutical Corporation -0.28% -11.64%

Financials

Sales 2024 * 963B 6.08B 8.31B Sales 2025 * 1,049B 6.62B 9.06B Capitalization 570B 3.6B 4.92B
Net income 2024 * 24.99B 158M 216M Net income 2025 * 26.92B 170M 232M EV / Sales 2024 * 0.56 x
Net cash position 2024 * 27.89B 176M 241M Net cash position 2025 * 33.49B 211M 289M EV / Sales 2025 * 0.51 x
P/E ratio 2024 *
22.8 x
P/E ratio 2025 *
21.2 x
Employees -
Yield 2024 *
0.81%
Yield 2025 *
0.9%
Free-Float 47.53%
More Fundamentals * Assessed data
Dynamic Chart
Cosmos Pharmaceutical's Attributable Profit Up 6.6% in Fiscal Nine Months MT
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024 CI
Cosmos Pharmaceutical’s Attributable Profit Up 2.6% in Fiscal H1 on Expansion of Stores MT
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024 CI
COSMOS Pharmaceutical Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending May 31, 2024, Payable on February 13, 2024; Provides Year Dividend Guidance for fiscal Year Ending May 31, 2024 CI
Cosmos Pharmaceutical’s Attributable Profit up marginally by 0.4% in Fiscal Q1 After Opening New Stores MT
COSMOS Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended August 31, 2023 CI
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024 CI
Cosmos Attributable Profit Increases 2.8% in Fiscal Year 2023 MT
COSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Year Ended May 31, 2023, Payable on August 3, 2023; Provides Dividend Guidance for the Second Quarter-End and Full Year of Full Year Ending May 31, 2024 CI
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024 CI
Cosmos Pharma's Attributable Profit Slides 1% in Fiscal Nine Months Amid New Store Openings MT
COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2023 CI
COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal year ending May 31, 2023 CI
Cosmos Pharma Books Marginal Rise in Fiscal H1 Attributable Profit Amid New Store Openings, Low-cost Strategy MT
More news
1 day-0.79%
1 week-0.28%
Current month-0.55%
1 month-0.10%
3 months-8.14%
6 months-4.13%
Current year-11.64%
More quotes
1 week
14 060.00
Extreme 14060
14 605.00
1 month
13 615.00
Extreme 13615
14 980.00
Current year
13 520.00
Extreme 13520
16 345.00
1 year
13 060.00
Extreme 13060
17 440.00
3 years
10 770.00
Extreme 10770
20 700.00
5 years
8 425.00
Extreme 8425
20 700.00
10 years
5 075.00
Extreme 5075
20 700.00
More quotes
Managers TitleAgeSince
President 43 03-03-31
Director of Finance/CFO 58 94-03-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 50 05-03-31
Director/Board Member 52 98-10-31
Director of Finance/CFO 58 94-03-31
More insiders
Date Price Change Volume
24-04-26 14,390 -0.79% 158,200
24-04-25 14,505 +0.62% 130,400
24-04-24 14,415 -0.35% 124,600
24-04-23 14,465 +1.87% 175,300
24-04-22 14,200 -1.59% 417,900

Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am

More quotes
COSMOS Pharmaceutical Corporation is a company primarily engaged in the operation of drug stores. The Company offers medical goods, including general self-medication products, tonic drinks, oral care products, nursing care products, vitamin supplements, health food products, diet food and dispensing. Cosmetic products include cosmetic products for women and men, hair care products and bath agents. Miscellaneous goods include baby goods, detergents, insecticides, deodorizers, bath goods, toiletries, cookware, gardening goods, automobile goods and clothing products. General food products include processed food products, daily food products, seasonings, confectionery, non-alcoholic beverages and alcoholic beverages. It also provides tobacco and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
14,390 JPY
Average target price
16,620 JPY
Spread / Average Target
+15.50%
Consensus